If you purchased Erasca Inc. (ERAS) stock between January 14, 2025 and April 26, 2026, you may qualify for compensation through an ongoing securities class action lawsuit. Filing your claim requires demonstrating that you held securities during the class period and incurred losses tied to the company’s alleged misrepresentations. The process unfolds in stages, with different deadlines for different types of participation—most notably, August 10, 2026 for investors seeking to serve as lead plaintiff.
An investor who bought Erasca shares at $18 per share in February 2026 and held through April 2026 would have faced devastating losses when the stock plummeted 48%, dropping from $19.15 to $9.90 in a single day following critical disclosures. This collapse erased $2.8 billion from the company’s market capitalization and triggered multiple law firms to pursue claims on behalf of affected shareholders. Understanding when and how to file ensures you don’t miss your opportunity to participate in the settlement process. The lawsuit hinges on allegations that Erasca made false statements about its lead drug candidate, ERAS-0015, portraying it as “best-in-class” while failing to disclose known patent infringement risks and a patient death linked to the treatment. These allegations form the basis for investor claims that the company concealed material information affecting stock value.
Table of Contents
- What Events Precipitated the Erasca ERAS Class Action Lawsuit?
- The Class Period: When Did the Alleged Deception Occur?
- Who Qualifies to File a Claim?
- How to File Your Claim: The Mechanics of Participation
- Understanding the Lead Plaintiff Application Deadline
- Calculating Your Damages and Recovery Expectations
- The Role of Multiple Law Firms and Claim Administration
- Critical Deadlines You Cannot Miss
- Frequently Asked Questions
What Events Precipitated the Erasca ERAS Class Action Lawsuit?
The lawsuit emerged from a cascade of disclosures in April 2026 that fundamentally altered investor perception of Erasca’s prospects. On April 27, 2026, the company revealed via SEC filing that a patient who received 24 milligrams of ERAS-0015 died approximately one month after starting treatment. This death represented a material safety event that the market had not previously priced into the stock. Simultaneously, the company faced patent infringement allegations from Revolution Medicines, which accused Erasca of infringing patents related to ERAS-0015’s pan-RAS molecular glue targeting solid tumors—the same intellectual property at the core of Erasca’s drug development strategy.
The core allegation in the lawsuit is that Erasca made misleading statements and comparisons regarding ERAS-0015’s therapeutic profile relative to competing treatments, specifically Revolution Medicines’ RMC-6236, while deliberately hiding the patent dispute and safety concerns. investors relied on these representations when making investment decisions. The failure to disclose known risks is the critical distinction—not that the drug failed in development, but that investors lacked information necessary to assess that failure before it became public. This scenario mirrors other biotech litigation where clinical setbacks or intellectual property disputes drive rapid re-valuations. The warning here: biotech investors should view any single therapy as carrying concentrated risk, and delays in disclosing safety events or patent challenges can trigger significant legal exposure for the company.
The Class Period: When Did the Alleged Deception Occur?
Erasca investors who purchased securities between January 14, 2025 and April 26, 2026 fall within the official class period. This span covers over a year of trading, during which the company publicly promoted ERAS-0015 and its clinical potential without disclosing the patent infringement risk or the patient death that would later emerge. The April 27, 2026 disclosure marked the inflection point—the date when previously unknown information entered the market, causing the stock to crater. The timeline is crucial because it defines eligibility: you must have purchased during this window to have a claim.
Someone who bought shares in December 2024 would not qualify, even if they held through the April 2026 collapse, because their purchase occurred before the class period began. Conversely, an investor who sold shares in late April 2026, just before the disclosure, would likely have avoided the worst losses but might still have grounds to claim if they can demonstrate they purchased during the class period and sold at a loss relative to their entry price. A limitation to understand: the class period does not extend to include investors who purchased after April 26, 2026, even if they bought shares that subsequently recovered or declined further. The cutoff date is mechanistic and reflects the date through which the company allegedly made misleading statements. This means late-arriving investors cannot participate, regardless of losses incurred.
Who Qualifies to File a Claim?
Any investor who purchased Erasca securities during the class period (January 14, 2025 through April 26, 2026) and held shares into the disclosure period qualifies for consideration. This includes individual retail investors, institutional funds, pension plans, and other entities that held ERAS stock. You do not need to hold shares continuously from purchase through the present; you qualify if you purchased during the window, though timing of sale affects your potential damages calculation. An example: an investor who purchased 500 shares at an average price of $17 per share in March 2026 and sold all 500 at $10 per share in May 2026 would have a loss of $3,500 before accounting for transaction costs and taxes.
This loss forms the basis for a damages claim. By contrast, an investor who purchased 100 shares at $12 per share and still held them at $9.90 per share would show an unrealized loss of $210 on that position. Both types of investors may have claims, though the calculation methodology can differ. Importantly, you do not need to have suffered a loss exceeding a minimum threshold; any demonstrable loss on your Erasca investment during the class period can form the basis for a claim. This differs from some shareholder litigation where threshold losses or minimum holding periods apply.
How to File Your Claim: The Mechanics of Participation
Claiming compensation typically involves submitting claim documentation through the settlement administrator appointed by the court. Investors must provide proof of purchase and sale, including transaction statements, brokerage confirmations, or tax records. The law firms representing the class—including Kirby McInerney LLP, Kahn Swick & Foti LLC, Hagens Berman, and Faruqi & Faruqi LLP—offer information about claim procedures on their websites and through published notices. The process generally requires providing your purchase date, purchase price, quantity of shares, sale date (if applicable), and sale price. You will also need to calculate your loss or provide supporting documentation showing your account value.
Most settlement administrators allow online filing, which expedites processing compared to paper submission. The trade-off is accuracy: submitting incomplete information or mismatched figures can delay processing or trigger requests for clarification. One practical consideration: gather your documentation now if you believe you have a claim. Brokerage statements older than a few years may require contacting your broker directly, and some firms archive older statements only upon request. The sooner you locate supporting documents, the more prepared you are to submit when claim windows open.
Understanding the Lead Plaintiff Application Deadline
Investors seeking to serve as the lead plaintiff (representative for the entire class) must submit applications by August 10, 2026. The lead plaintiff role carries significance: this investor effectively directs the litigation strategy alongside counsel and receives recognition in court filings. Not all investors will want this responsibility, and few are ultimately selected. The deadline for applications is firm and non-negotiable; missing August 10, 2026 means forfeiting the opportunity to apply. To qualify as lead plaintiff, you must have (1) purchased Erasca securities during the class period, (2) incurred losses on your purchase, and (3) be able to demonstrate your investment was among the largest in the class.
Courts prioritize applicants with substantial losses and commitment to the litigation. An investor who purchased $5,000 of stock and lost $2,000 might be considered; an investor with only $500 in losses likely would not. The application process requires filing with the court, not simply contacting the law firms. A limitation: being selected as lead plaintiff does not guarantee you recover more than other class members. Your role is organizational and fiduciary; compensation is determined by the settlement or judgment and distributed pro-rata based on documented losses, the same as other claimants. However, some courts award lead plaintiffs modest expense reimbursements.
Calculating Your Damages and Recovery Expectations
Your damages claim quantifies the loss you incurred on Erasca securities attributable to the alleged misrepresentation period. The basic calculation is: (purchase price – sales price) × shares purchased. If you bought 200 shares at $16 per share ($3,200 invested) and sold at $9.50 per share ($1,900 received), your loss is $1,300. Courts and settlement administrators use this framework, though some adjust for inflation, transaction costs, or other factors depending on the specific settlement terms.
Recovery expectations must be tempered. In securities class actions, investors typically recover 5 to 30 cents per dollar of claimed loss, depending on the strength of evidence, defendant willingness to settle, and the overall insurance coverage available. An investor with a $1,300 claim might ultimately recover $65 to $390 if the settlement yields a 5 to 30 percent recovery rate. This is not insignificant, but it is not full restitution. The settlement fund itself depends on negotiations between the defense and plaintiffs’ counsel and approval by the court.
The Role of Multiple Law Firms and Claim Administration
Four major law firms—Kirby McInerney, Kahn Swick & Foti, Hagens Berman, and Faruqi & Faruqi—have announced representation of Erasca plaintiffs. Typically, one firm serves as lead counsel coordinating the litigation, while others represent subsets of the class or work cooperatively. From an investor’s perspective, this multiplicity means you may receive notices from different firms; you need only file your claim once, through the court-appointed settlement administrator.
Selecting between law firms or determining which one represents you can be unclear for individual investors. In practice, if you contacted one firm about your potential claim, you may be considered part of that firm’s group, but official assignment occurs through the settlement administrator. The key point: firm selection rarely affects your recovery amount, which is determined by the settlement as a whole, not by which law firm handled your case. What does matter is that you submit your claim through the proper channel before the deadline.
Critical Deadlines You Cannot Miss
August 10, 2026 is the mandatory deadline for lead plaintiff applications. This date is non-negotiable and is set by court order; courts do not routinely extend lead plaintiff deadlines because doing so would delay case management. If you intend to apply, mark this date and submit your application well before the deadline, accounting for mail delivery or online system delays.
The class period itself—January 14, 2025 through April 26, 2026—defines who qualifies. Securities purchases outside this window do not create a claim, regardless of subsequent losses. The April 27, 2026 disclosure date marks when material information became public, triggering the stock decline and activating investor harm claims. Understanding these dates ensures you know whether your transactions fall within scope.
- —
Frequently Asked Questions
Do I need to hire a lawyer to file my claim?
No. Most securities class actions are administered by a court-appointed settlement administrator. You file directly through that administrator using the forms provided, without needing private counsel.
What if I bought Erasca shares before January 14, 2025?
If your purchase occurred before the class period began, you cannot claim losses on that position, even if you held and sold during or after April 2026.
Will I receive the full value of my losses?
Unlikely. Securities class action recoveries typically range from 5 to 30 cents per dollar of claimed loss, depending on the settlement terms and the number of claimants.
What documents do I need to prove my claim?
You need brokerage statements, trade confirmations, or tax documents showing your purchase date, purchase price, quantity purchased, and—if applicable—sale date and sale price.
If I missed the lead plaintiff deadline, can I still recover?
Yes. The lead plaintiff role is optional and represents only a small fraction of claimants. Ordinary class members file regular claims and recover proportionally based on proven losses.
What happens if Erasca files for bankruptcy?
The lawsuit proceeds against the company’s insurance and assets. Bankruptcy can affect recovery amounts, but ongoing settlements are typically prioritized in bankruptcy proceedings. —